Tumor-derived soluble PD-L1 drives immune checkpoint inhibitor (ICI) resistance and has recently been reported to be removed by therapeutic plasma exchange (TPE). Here, the authors report a phase I clinical trial investigating the combination of radiotherapy, TPE, and ICI rechallenge in patients with ICI-refractory metastatic melanoma with high PD-L1.
- Jacob J. Orme
- Henan Zhang
- Sean S. Park
